Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$62 Mln
P/E Ratio
--
P/B Ratio
0.88
Industry P/E
--
Debt to Equity
0
ROE
-1.9 %
ROCE
--
Div. Yield
0 %
Book Value
3.39
EPS
--
CFO
$-614.44 Mln
EBITDA
$-774.85 Mln
Net Profit
$-914.61 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Adverum Biotechnologies (ADVM)
| -37.69 | -46.11 | -35.19 | -71.44 | -36.56 | -53.20 | -38.50 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Adverum Biotechnologies (ADVM)
| -37.74 | 29.94 | -67.05 | -83.76 | -5.90 | 265.71 | -9.95 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.68 | 78.84 | -- | -62.96 | |
| 8.54 | 801.08 | -- | -69.5 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 24.99 | 2,881.32 | -- | -14.59 |
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used... for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California. Read more
President, CEO & Director
Dr. Laurent Fischer
President, CEO & Director
Dr. Laurent Fischer
Headquarters
Redwood City, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Adverum Biotechnologies Inc (ADVM) stood at $ 311 Mln as on 31-Mar-25
The share price of Adverum Biotechnologies Inc (ADVM) is $2.91 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Adverum Biotechnologies Inc (ADVM) has given a return of -36.56% in the last 3 years.
Adverum Biotechnologies Inc (ADVM) has a market capitalisation of $ 62 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Adverum Biotechnologies Inc (ADVM) is 0.88 times as on 25-Apr-2025, a 62% discount to its peers’ median range of 2.29 times.
Since, TTM earnings of Adverum Biotechnologies Inc (ADVM) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Adverum Biotechnologies Inc (ADVM) and enter the required number of quantities and click on buy to purchase the shares of Adverum Biotechnologies Inc (ADVM).
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing BGTF-027 (AAV.7m8-L-opsin), a novel gene therapy product candidate designed to deliver a functional copy of the OPN1LW gene to the foveal cones of patients suffering from blue cone monochromacy. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Ray Therapeutics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
The CEO & director of Dr. Laurent Fischer. is Adverum Biotechnologies Inc (ADVM), and CFO & Sr. VP is Dr. Laurent Fischer.
There is no promoter pledging in Adverum Biotechnologies Inc (ADVM).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
867
|
|
|
290
|
|
|
80
|
|
|
8
|
| Adverum Biotechnologies Inc. (ADVM) | Ratios |
|---|---|
|
Return on equity(%)
|
-155.16
|
|
Operating margin(%)
|
4147.19
|
|
Net Margin(%)
|
6410.38
|
|
Dividend yield(%)
|
0
|
No, TTM profit after tax of Adverum Biotechnologies Inc (ADVM) was $0 Mln.
$-0.06
(
